Allied (ALID) 10-Q19 Apr 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover	6 Months Ended
Cover	Feb. 29, 2024 shares
Cover [Abstract]
Entity Registrant Name	ALLIED CORP.
Entity Central Index Key	0001575295
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Feb. 29, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding	105,816,904
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56002
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	33-1227173
Entity Address Address Line 1	1405 St. Paul St.
Entity Address Address Line 2	Suite 201
Entity Address City Or Town	Kelowna
Entity Address State Or Province	BC
Entity Address Country	CA
Entity Address Postal Zip Code	V1Y 9N2
City Area Code	877
Local Phone Number	255-4337
Entity Interactive Data Current	Yes

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Current assets
Cash	$ 101,648	$ 209,736
Inventory (Note 3)	443,690	107,510
Other receivables	171,001	134,482
Prepaid expenses	50,748	18,852
Total current assets	767,087	470,580
Deposits and advances (Note 4)	19,083	26,354
Right-of-use assets (Note 7)	108,566	109,301
Property, plant and equipment (Note 5)	1,350,193	1,417,192
Intangible assets (Note 6)	44,874	40,301
Total assets	2,289,803	2,063,728
Current liabilities
Accounts payable and accrued liabilities	2,627,129	2,393,359
Due to related parties (Note 11)	942,892	693,292
Current portion of lease liabilities (Note 7)	12,070	10,745
Loans payable (Note 8)	2,363,194	2,027,348
Secured convertible notes payable (Note 9)	3,774,891	3,724,891
Total current liabilities	9,720,176	8,849,635
Lease liabilities, net of current portion (Note 7)	96,496	98,556
Total liabilities	9,816,672	8,948,191
Stockholders' deficiency
Preferred stock - 50,000,000 shares authorized, $0.0001 par value Nil shares issued and outstanding	0	0
Common stock - 300,000,000 shares authorized, $0.0001 par value; 105,816,904 shares issued and outstanding (101,592,914 - par value $0.0001 - August 31, 2023)	10,582	10,160
Additional paid in capital	40,610,375	39,404,667
Common stock issuable	30,000	80,000
Accumulated deficit	(47,310,835)	(45,608,336)
Accumulated other comprehensive loss	(866,991)	(770,954)
Total stockholders' deficit	(7,526,869)	(6,884,463)
Total liabilities and stockholders' deficit	$ 2,289,803	$ 2,063,728

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Feb. 29, 2024	Aug. 31, 2023
Stockholders' equity (deficit)
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares issued	105,816,904	101,592,914
Common stock, shares outstanding	105,816,904	101,592,914

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Revenues
Sales	$ 0	$ 0	$ 19,039	$ 69,625
Cost of sales (Note 3)	0	0	(2,003)	(25,958)
Gross margin	0	0	17,036	43,667
Expenses
Amortization and depreciation	27,136	31,269	62,555	57,429
Consulting fees (Note 10 and 11)	481,829	813,878	923,316	1,660,535
Foreign exchange loss (gain)	(12,349)	365	(60,670)	(2,865)
Interest expense and bank charges	118,826	121,304	237,472	240,046
Office and miscellaneous	32,927	887,106	183,902	957,112
Professional fees	124,003	119,906	184,792	297,096
Travel	429	2,588	2,276	10,029
Operating expenses	772,801	1,976,416	1,533,643	3,219,382
Loss before other items	(772,801)	(1,976,416)	(1,516,607)	(3,175,715)
Other income and expenses
Interest expense	(93,025)	(87,821)	(185,892)	(171,020)
Loss on debt extinguishment	0	0	0	(27,043)
Total other expenses	(93,025)	(87,821)	(185,892)	(198,063)
Net loss	(865,826)	(2,064,237)	(1,702,499)	(3,373,778)
Other comprehensive loss
Foreign currency translation adjustments	(79,415)	696,142	(96,037)	542,142
Comprehensive loss	$ (945,241)	$ (1,368,095)	$ (1,798,536)	$ (2,831,636)
Basic and diluted loss per share	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.03)
Weighted average number of common shares outstanding	105,792,245	97,038,154	104,205,478	96,529,807

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Stockholders Deficit (Unaudited) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Issuable [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance, shares at Aug. 31, 2022		93,967,594
Balance, amount at Aug. 31, 2022	$ (1,282,397)	$ 9,397	$ 33,999,090	$ 540,000	$ (34,932,665)	$ (898,219)
Shares issued for cash, shares		2,925,000
Shares issued for cash, amount	630,000	$ 292	1,169,708	(540,000)	0	0
Share issuance costs	(12,792)	$ 0	(12,792)	0	0	0
Shares issued to settle debts, shares		145,560
Shares issued to settle debts, amount	86,572	$ 15	86,557	0	0	0
Stock-based compensation	545,171	0	545,171	0	0	0
Comprehensive loss for the year	(1,463,541)	$ 0	0	0	(1,309,541)	(154,000)
Balance, shares at Nov. 30, 2022		97,038,154
Balance, amount at Nov. 30, 2022	(1,496,987)	$ 9,704	35,787,734	0	(36,242,206)	(1,052,219)
Balance, shares at Aug. 31, 2022		93,967,594
Balance, amount at Aug. 31, 2022	(1,282,397)	$ 9,397	33,999,090	540,000	(34,932,665)	(898,219)
Stock-based compensation	1,119,246
Balance, shares at Feb. 28, 2023		97,038,154
Balance, amount at Feb. 28, 2023	(2,050,055)	$ 9,704	36,361,809	240,952	(38,306,443)	(356,077)
Balance, shares at Nov. 30, 2022		97,038,154
Balance, amount at Nov. 30, 2022	(1,496,987)	$ 9,704	35,787,734	0	(36,242,206)	(1,052,219)
Stock-based compensation	574,075	0	574,075	0	0	0
Comprehensive loss for the year	(1,368,095)	0	0	0	(2,064,237)	696,142
Shares subscribed	240,952	$ 0	0	240,952	0	0
Balance, shares at Feb. 28, 2023		97,038,154
Balance, amount at Feb. 28, 2023	(2,050,055)	$ 9,704	36,361,809	240,952	(38,306,443)	(356,077)
Balance, shares at Aug. 31, 2023		101,592,914
Balance, amount at Aug. 31, 2023	(6,884,463)	$ 10,160	39,404,667	80,000	(45,608,336)	(770,954)
Shares issued for cash, shares		250,000
Shares issued for cash, amount	0	$ 25	49,975	(50,000)	0	0
Stock-based compensation	143,653	0	143,653	0	0	0
Comprehensive loss for the year	(853,295)	0	0	0	(836,673)	(16,622)
Shares subscribed	346,000	$ 0	0	346,000	0	0
Balance, shares at Nov. 30, 2023		101,842,914
Balance, amount at Nov. 30, 2023	(7,248,105)	$ 10,185	39,598,295	376,000	(46,445,009)	(787,576)
Balance, shares at Aug. 31, 2023		101,592,914
Balance, amount at Aug. 31, 2023	(6,884,463)	$ 10,160	39,404,667	80,000	(45,608,336)	(770,954)
Stock-based compensation	366,708
Balance, shares at Feb. 29, 2024		105,816,904
Balance, amount at Feb. 29, 2024	(7,526,869)	$ 10,582	40,610,375	30,000	(47,310,835)	(866,991)
Balance, shares at Nov. 30, 2023		101,842,914
Balance, amount at Nov. 30, 2023	(7,248,105)	$ 10,185	39,598,295	376,000	(46,445,009)	(787,576)
Shares issued for cash, shares		3,931,990
Shares issued for cash, amount	440,398	$ 393	786,005	(346,000)	0	0
Stock-based compensation	223,055	0	223,055	0	0	0
Comprehensive loss for the year	(945,241)	$ 0	0	0	(865,826)	(79,415)
Share issuance costs, shares		42,000
Share issuance costs, amount	3,024	$ 4	3,020	0	0	0
Balance, shares at Feb. 29, 2024		105,816,904
Balance, amount at Feb. 29, 2024	$ (7,526,869)	$ 10,582	$ 40,610,375	$ 30,000	$ (47,310,835)	$ (866,991)

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023
Condensed Consolidated Interim Statements of Cash Flows (Unaudited)
Net loss for the period	$ (1,702,499)	$ (3,373,778)
Adjustment to net loss for the period for non-cash items
Accrued interest	421,524	406,867
Amortization and depreciation	62,555	57,429
Loss on debt extinguishment	0	27,043
Stock-based compensation - options	366,708	1,119,246
Fair value of finder's shares	3,024	0
Changes in non-cash working capital balance:
(Increase) decrease in other receivables	(30,232)	85,993
(Increase) decrease in prepaid expenses	(31,896)	7,038
Decrease in deposits and advances	8,214	24,086
(Decrease) increase in accounts payable and accrued liabilities	(43,690)	266,810
Increase in due to related parties	249,600	113,303
Increase in inventory	(248,109)	(459,605)
Net cash provided by used in operating activities	(944,801)	(1,725,568)
Investing activities
Purchase of intangible assets	(6,501)	(3,964)
Purchase of property, plant, and equipment	(2,038)	(80,858)
Net cash provided by used in investing activities	(8,539)	(84,822)
Financing activities
Advance from related parties	55,600	0
Proceeds from loan payable	100,000	0
Proceeds from convertible notes payable	50,000	380,000
Proceeds from the issuance of common stock	786,398	617,208
Proceeds for subscriptions of stock issuable	0	240,952
Net cash provided by used in financing activities	991,998	1,238,160
Increase (decrease) in cash	38,658	(572,230)
Effect of exchange rate on changes of cash	(146,746)	641,127
Cash, beginning of period	209,736	96,043
Cash, end of period	101,648	164,940
Supplemental cash flow disclosures:
Income taxes paid	0	0
Interest paid	$ 0	$ 0

Nature of operations reverse ta

Nature of operations reverse takeover transaction and going concern	6 Months Ended
	Feb. 29, 2024
Nature of operations reverse takeover transaction and going concern
Nature of operations, reverse take-over transaction and going concern	1. Nature of operations, reverse take-over transaction and going concern a) Nature of operations Allied Corp. (the “Company or Allied”) was incorporated in the State of Nevada on February 3, 2013. On July 1, 2019, the Company changed its name to Allied Corp. The head office and the registered office of the Company are located at 1405 St. Paul Street, Kelowna BC V1Y 2E4. The Company’s business plan is to discover new medical technologies some of which are cannabis derived to target full scope therapy and support for trauma survivors, military veterans and first responders, however the Company has not begun such operations nor obtained the required permits to begin such operations. On September 10, 2019, the Company was acquired in a reverse takeover (“RTO”) transaction and the RTO is considered a purchase of the Company’s net assets by AM (Advanced Micro) Biosciences, Inc. (“AM Biosciences”). For accounting purposes, the legal subsidiary, AM Biosciences has been treated as the acquirer and Allied Corp., the legal parent, has been treated as the acquiree. Accordingly, these consolidated financial statements reflect a continuation of the financial position, operating results, and cash flow of the Company’s legal subsidiary, AM Biosciences from the date of incorporation on September 13, 2018. On February 18, 2020, the Company acquired all the issued and outstanding share capital of a Colombian company, Allied Colombia S.A.S (“Allied Colombia”). The assets, liabilities and results of Allied Colombia are consolidated in these financial statements beginning from the February 18, 2020 acquisition date. As at February 29, 2024, Allied Colombia has a licensed cannabis farm in Colombia. b) Going concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company incurred a net loss for the six months ended February 29, 2024 of $1,702,499, has generated minimal revenue and as at February 29, 2024 has a working capital deficit of $8,953,089. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise sufficient financing to acquire or develop a profitable business. Management intends on financing its operations and future development activities largely from the sale of equity securities with some additional funding from other traditional financing sources, including related party loans until such time that funds provided by future planned operations are sufficient to fund working capital requirements. c) Business Risks While some states in the United States have authorized the use and sale of cannabis, it remains illegal under federal law and the approach to enforcement of U.S. federal laws against cannabis is subject to change. The Company plans to engage in cannabis-related activities in the United States, only if and when cannabis operations are federally legalized. On January 4, 2018, the then United States Attorney General Jeff Sessions issued a memorandum to United States district attorneys (the “Sessions Memorandum”) which rescinded previous guidance from the United States Department of Justice specific to cannabis enforcement in the United States, including the Cole Memorandum. With the Cole Memorandum rescinded, United States federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of United States federal law. Since that time, United States district attorneys have taken no legal action against state law compliant entities, and the Biden administration is generally anticipated to seek federal decriminalization of state legal cannabis activity. Nevertheless, a significant change in the federal government’s enforcement policy with respect to current federal laws applicable to cannabis could cause significant financial damage to the Company. The Company may be irreparably harmed by a change in enforcement policies of the federal government depending on the nature of such change. Given the current illegality of cannabis under United States federal law, the Company’s ability to access both public and private capital may be hindered by the fact that certain financial institutions are regulated by the United States federal government and are thus prohibited from providing financing to companies engaged in cannabis related activities. The Company’s ability to access public capital markets in the United States is directly hindered as a result. The Company may, however, be able to access public and private capital markets in the United States through institutions which are not regulated by the United States federal government, in Canada, and in many other countries in order to support continuing operations.

Significant accounting policies

Significant accounting policies	6 Months Ended
Significant accounting policies	Feb. 29, 2024
Significant accounting policies
Significant accounting policies	2. Significant accounting policies Business Presentation These unaudited condense consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), and are expressed in United States dollars. The Company’s fiscal year end is August 31. These interim unaudited financial statements have been prepared in accordance with US GAAP for interim financial information and with the instructions to Securities and Exchange Commission (“SEC”) Form 10-Q. They do not include all of the information and footnotes required by US GAAP for complete financial statements. Therefore, these interim financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended August 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC. The consolidated financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at February 29, 2024, and the results of its operations for the six months ended February 29, 2024, and cash flows for the six months ended February 29, 2024. The results of operations for the period ended February 29, 2024 are not necessarily indicative of the results to be expected for future quarters or the full year. The significant accounting policies followed are: a) Principles of consolidation These consolidated financial statements include accounts of Allied Corp. and its wholly-owned subsidiaries, including AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation. b) Cash and cash equivalents Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. Cash equivalents are short-term, highly liquid investments with maturities within three months when acquired. The Company did not have any cash equivalents as of February 29, 2024 and August 31, 2023. c) Property, plant and equipment Property, plant and equipment are stated at cost. The Company depreciates the cost of property, plant and equipment over their estimated useful lives at the following annual rates and methods: Farm facility and equipment 1 - 10 years straight-line basis Office and computer equipment 5 - 10 years straight-line basis Land equipment 10 years straight-line basis d) Inventory Inventory is comprised of raw materials, supplies, vegetative and flowering plants, dried flower, diluted crude and CBD isolates available for sale, and purchased cannabis products. Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows. e) Intangible assets Intangible assets include licenses which are being amortized over their estimated useful lives of 10 years. The Company’s licenses are amortized over their economic or legal life on a straight-line basis, whichever is shorter. The licenses have been amortized from the date of acquisition. The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives. For long-lived assets, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value. f) Long-lived assets In accordance with ASC 360, Property, Plant and Equipment g) Foreign currency translation and functional currency conversion Items included in these consolidated financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entities operate (the “functional currency”). Prior to September 10, 2019, the Company’s functional currency was the Canadian dollar. Translation gains and losses from the application of the U.S. dollar as the reporting currency during the period that the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss. The Company re-assessed its functional currency and determined as at September 10, 2019, its functional currency changed from the Canadian dollar to the U.S. dollar based on management’s analysis of changes in our organization. The change in functional currency was accounted for prospectively from September 10, 2019 and prior period financial statements were not restated for the change in functional currency. For periods commencing September 10, 2019, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after September 10, 2019 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transactions. Foreign exchange gains and losses are included in the statement of operations and comprehensive loss as foreign exchange gains. The Company assessed the functional currency for Allied Colombia to be the Colombian peso. The functional currency for all other subsidiaries is the U.S. dollar. h) Share issuance costs Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued. i) Research and development costs Research and development costs are expensed as incurred. During the six months ended February 29, 2024, the Company incurred research and development costs of $nil (February 28, 2023 – $nil). j) Advertising costs Advertising costs are expensed as incurred. During the six months ended February 29, 2024, the Company incurred advertising costs of $631 (February 28, 2023 – $4,913). k) Revenue recognition The Company’s revenue is comprised of sales of cannabis products. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data. l) Net income (loss) per common share Net income (loss) per share is calculated in accordance with ASC 260, Earnings per Share Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding. m) Income taxes The Company accounts for income taxes under ASC 740, Income Taxes n) Related party transactions Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts. o) Significant accounting estimates and judgments The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern as described in Note 1. p) Financial instruments ASC 825, Financial Instruments Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments consist principally of cash, due from related parties, accounts payable, note payable, and convertible notes payable. The fair value of cash when applicable is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all other financial instruments which are categorized as loans and receivables approximate their current fair values because of their nature and respective relatively short maturity dates or current market rates of interest for similar instruments. For certain of the Company’s financial instruments, including accounts payable, due from related parties, notes and loans payable, the carrying amounts approximate their fair values due to the short maturities. The Company does not have any assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet as of February 29, 2024 and August 31, 2023 other than cash. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. q) Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. The Company uses the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7 – Leases. r) Recent accounting pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective September 1, 2022. The adoption of ASU 2020-06 did not have an impact on the Company’s financial statements. The Company does not expect that recent accounting pronouncements or changes in accounting pronouncements during the six months ended February 29, 2024, are of significance or potential significance to the Company.

Inventory

Inventory	6 Months Ended
Inventory	Feb. 29, 2024
Inventory
Inventory	3. Inventory Inventory is comprised of the following items: February 29, 2024 August 31, 2023 Work in progress $ 47,163 $ 80,094 Finished goods 396,527 27,416 Total inventory $ 443,690 $ 107,510 The costs of inventory include but are not limited to labor, utilities, nutrition and irrigation, overhead and the depreciation of manufacturing equipment and production facilities, and amortization of licenses determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and rent of grow facility. The Company began production in Colombia in late 2020, when the Company obtained approval for its strains of products. During the current period, certain costs were determined based on the actual usage of production space as compared to the normal predetermined operational production of the facility based on capacity as the Company gradually started to grow products and prepared the facility ready. During the six months ended February 29, 2024, the Company recorded a $nil write-off of inventory costs to its net realizable value of $443,690. During the year ended August 31, 2023, the Company recorded a $43,861 write-off of inventory costs for CBD isolates and other derivative products to reduce to its net realizable value of $nil. In addition, the Company recorded additional $1,463,157 write-off of inventory costs to its net realizable value of $107,510.

Deposits and advances

Deposits and advances	6 Months Ended
Deposits and advances	Feb. 29, 2024
Deposits and advances
Deposits and advances	4. Deposits and advances February 29, 2024 August 31, 2023 Prepayments for construction facility in Colombia $ 19,083 $ 26,354 Total deposits and advances $ 19,083 $ 26,354 The Company paid certain vendors for the construction of farm facilities in Colombia in advance. At February 29, 2024, the prepayments totaled $19,083 (August 31, 2023 – $26,354).

Property plant and equipment

Property plant and equipment	6 Months Ended
Property plant and equipment	Feb. 29, 2024
Property plant and equipment
Property plant and equipment	5. Property, plant and equipment At February 29, 2024, property, plant and equipment consisted of: Construction in process Farm facility and equipment Office and computer equipment Land equipment Total Cost August 31, 2023 $ 429,749 $ 1,346,373 $ 29,952 $ 29,525 $ 1,835,599 Additions - 2,038 - - 2,038 Foreign exchange 18,310 29,083 1,276 1,258 49,927 February 29, 2024 $ 448,059 $ 1,377,494 $ 31,228 $ 30,783 $ 1,887,564 Accumulated depreciation August 31, 2023 $ - $ 404,559 $ 7,700 $ 6,148 $ 418,407 Additions - 100,686 1,614 1,492 103,792 Foreign exchange - 14,514 363 295 15,172 February 29, 2024 $ - $ 519,759 $ 9,677 $ 7,935 $ 537,371 Net book value August 31, 2023 $ 429,749 $ 941,814 $ 22,252 $ 23,377 $ 1,417,192 February 29, 2024 $ 448,059 $ 857,735 $ 21,551 $ 22,848 $ 1,350,193 As of February 29, 2024 and August 31, 2023, the construction in process has not been in use.

Intangible assets

Intangible assets	6 Months Ended
Intangible assets	Feb. 29, 2024
Intangible assets
Intangible assets	6. Intangible assets At February 29, 2024, intangible assets consisted of: Cost $ Foreign exchange $ Accumulated amortization $ Accumulated impairment $ February 29, 2024 Net carrying value $ August 31, 2023 Net carrying value $ Cannabis licenses 5,457,911 (468,035 ) (1,143,335 ) (3,801,667 ) 44,874 40,301 5,457,911 (468,035 ) (1,143,335 ) (3,801,667 ) 44,874 40,301 On February 17, 2020, the Company acquired $5,435,334 of licenses as part of the acquisition of Allied Colombia. The licenses acquired are issued by the Republic of Colombia and include the use of seeds for growing Cannabis, production of derivatives from Cannabis for medicinal and scientific use, cultivation of Cannabis plants, and producer of seeds. The Company recorded amortization of these licenses of $658,836 for the year ended August 31, 2021, of which $158,121 was included in cost of inventory. Management acquired the licenses with a plan to operate in Colombia and believed the amounts paid for the licenses would be recovered from future operations. The Company has only recently started its operations in Colombia and has limited history on which to base future outcomes from operations including cash flows. Cannabis and hemp are considered to be an emerging industry and Colombia does not yet have a sufficiently established observable legal market in which the Company could sell its Cannabis or hemp flower and CBD or THC extracts. Laws and regulations in Colombia are evolving and there is uncertainty in what will be legally permissible in a future market and what prices and demand there would be in Colombia for the Company’s products. At the present, the Company’s export activities are regulated and restricted by Colombian law and it is uncertain whether future changes in law would favorably impact the Company’s operations. Due to the uncertainty in the timing and amount of future cash flows from operations the Company has written down its licenses to the estimated recoverable amount. During the year ended August 31, 2021, the Company recorded impairment of intangible assets in the amount of $2,687,695. During the six months ended February 29, 2024, the Company recorded amortization of $2,804 (COP 12,732,615) (February 28, 2023 - $5,683 (COP 26,881,413)).

Leases

Leases	6 Months Ended
Leases	Feb. 29, 2024
Leases
Leases	7. Leases The Company accounts for leases under ASC 842, Leases The Company did not have any leases until the acquisition of Allied Colombia during the year ended August 31, 2020. The acquisition resulted in the addition of $82,398 of operating lease assets and liabilities. During the year ended August 31, 2021, the Company re-measured its lease liabilities under this lease as the criteria was met for additional monthly payment when the Company started production as outlined in the lease agreement, resulting in additional lease liabilities of $70,705. On August 10, 2021, the Company entered into another lease for additional land in Colombia with monthly payment of $2,647 (COP9,970,675) for 12.5 hectares which is intended for use of outdoor cultivation, resulting in additional lease liabilities of $104,902. The lease is for 5 years, and expires in July 2026. Management has assessed the lease as an operating lease. Effective August 31, 2023, the Company terminated the lease. Pursuant to ASC 842-20 upon the termination of the lease, the Company derecognized the lease related asset and liability and included any consideration paid or received upon termination that was not already included in the lease payments in the gain or loss on termination of the lease. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the ROU asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term. ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. At February 29, 2024, the Company did not have any finance leases. At February 29, 2024, the weighted average remaining operating lease term was 6 years and the weighted average discount rate associated with operating leases was 15%. The components of lease expenses were as follows: $ Operating lease cost: Amortization of right-of-use assets 8,201 Interest on lease liabilities 5,277 Total operating lease cost 13,478 The following table provides supplemental cash flow and other information related to leases for the six months ended February 29, 2024: $ Lease payments 13,478 Supplemental balance sheet information related to leases as of February 29, 2024 are as below: $ Cost 159,870 Accumulated amortization (30,077 ) Foreign exchange (21,227 ) Net carrying value at February 29, 2024 108,566 Future minimum lease payments related to lease obligations are as follows: $ 2024 13,774 2025 27,547 2026 27,547 2027 27,547 2028 27,547 2029 27,547 2030 13,774 Total minimum lease payments 165,283 Less: amount of lease payments representing effects of discounting (56,717 ) Present value of future minimum lease payments 108,566 Less: current obligations under leases (12,070 ) Lease liabilities, net of current portion 96,496

Loans payable

Loans payable	6 Months Ended
Loans payable	Feb. 29, 2024
Loans payable
Loans payable	8. Loans payable a) In June 2020, the Company entered into a financing agreement to finance the buildings described in Note 4(a). Pursuant to the agreement, the Company financed $1,253,772 of the purchase price. The Company paid $71,023 at commencement date on May 29, 2020 and would make six monthly interest payments of $37,613 commencing June 20, 2020 and repay the principal of $1,253,772 on November 20, 2020. The loan was extended after the initial maturity date. On December 27, 2021, the Company entered into an amendment agreement. Pursuant to the amendment, the Company will make 27 monthly payments starting on January 20, 2022. For the first 3 months, the Company will make monthly payments of $37,613. For the remaining 24 months, the Company will make monthly payments of $66,288. If the first 6 monthly payments are made on time, the Company may prepay the unamortized loan balance with a 2% penalty of the remaining balance. During the six months ended February 29, 2024, the Company paid interest in the amount of $nil (2023 - $nil). As of February 29, 2024, the Company has missed 20 monthly payments and the balance owing is $1,968,327 (August 31, 2023 - $1,742,648). b) On December 17, 2021, the Company entered into a financing agreement to finance an equipment purchase. On March 31, 2022, the agreement was amended to remove shipping charges. Pursuant to the amended agreement, the Company financed $295,543 of the purchase price with an interest rate of 8% per annum. The Company will make 21 monthly principal and interest payments of $15,000 and a final payment of $633 in September 2023. During the six months ended February 29, 2024, the Company paid interest in the amount of $nil (2023 - $nil). As of February 29, 2024, the Company has missed 24 monthly payments and the balance owing is $294,867 (August 31, 2023 - $284,700). c) On January 3, 2024, a holder of the Company’s convertible notes provided a short term loan of $100,000 (August 31, 2023 - $nil). The amount is unsecured, non-interest bearing, and due on demand.

Secured convertible notes payab

Secured convertible notes payable	6 Months Ended
Secured convertible notes payable	Feb. 29, 2024
Secured convertible notes payable
Secured convertible notes payable	9. Secured convertible notes payable The Company has granted each and every of the secured convertible note holders a continuing security interest in, a general lien upon, and aright of set-off against all existing and future assets and property under the terms of a security agreement. a) On January 23, 2020, the Company issued two convertible notes with principal amounts of $400,000 and $200,000, respectively, with a total face value of $600,000 (the “Notes”) and warrants to purchase 240,000 shares of the Company’s common stock at $1.25 per share for 1 year. The Notes were issued with an original discount of $12,000, and bear interest at 10% per annum compounded monthly. The notes mature on July 20, 2020 and are convertible into shares of the Company’s common stock at any time prior to maturity at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Notes or warrants under ASC 815-15, Derivatives and Hedging The relative fair values of the convertible notes and the warrants were $470,467 and $117,533 respectively. The effective conversion price was then determined to be $0.98. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $115,383 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $108,100 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $364,517. The beneficial conversion feature of $115,383, the original issue discount of $12,000 and the relative fair value of the warrants of $108,100 discounted the carrying value of the convertible debt on the date of issue. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. On June 30, 2020, the Company repaid $200,000 of the $600,000 note which left $200,000 outstanding on each note. i. First Modification: On July 1, 2020, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 5% per annum. The maturity date of the convertible notes was amended to due on demand on or before October 31, 2020. In consideration for extending the maturity date, the Company issued to the convertible note holders 16,000 common shares of the Company and warrants to purchase additional 320,000 common shares of the Company at $1.25 per share expiring October 31, 2021. Each note holder received 8,000 common shares and 160,000 warrants. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment The extended convertible notes had a total carrying value of $400,000. As the common shares and warrants were issued as consideration for extending the convertible notes, the fair value of the common share and warrants of $218,397 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $220,065. ii. Second Modification: On November 1, 2020, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or before March 31, 2021. In consideration for extending the maturity date, the Company agreed to issue to the convertible note holders 100,000 common shares of the Company. Each note holder received 50,000 common shares. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment The extended convertible notes had a total carrying value of $400,000. As the common shares were issued as consideration for extending the convertible notes, the fair value of the common share of $110,000 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $110,000. iii. Third Modification: On March 31, 2021, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 10% per annum. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or before September 30, 2021. In consideration for extending the maturity date, the Company agreed to issue to the convertible note holders 20,000 common shares of the Company. Each note holder received 10,000 common shares. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment The extended convertible notes had a total carrying value of $400,000. As the common shares were issued as consideration for extending the convertible notes, the fair value of the common share of $20,000 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $20,000. iv. Fourth Modification: On October 1, 2021, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 10% per annum. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or after March 31, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. v. Fifth Modification: On March 31, 2022, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 10% per annum. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or after September 30, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. As at February 29, 2024, the Company has recorded accrued interest of $117,041 (August 31, 2023 - $97,205), which is included in accounts payable and accrued liabilities on the consolidated balance sheets. As of February 29, 2024, the outstanding principal owing is $400,000 (August 31, 2023 - $400,000). On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and conversion price. b) On September 29, 2020, the Company issued a convertible note with a fair value of $163,341 (the “Note”) and warrants to purchase 130,673 shares of the Company’s common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after March 27, 2021. The Note was convertible into shares of the Company’s common stock at any time prior to March 27, 2021 at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, Derivatives and Hedging The relative fair values of the convertible note and the warrants were $85,330 and $78,011 respectively. The effective conversion price was then determined to be $0.65. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $85,330 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $78,011 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. i. First Modification: On March 31, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before September 30, 2021. In consideration for extending the maturity date, the Company issued to the convertible note holder 8,268 common shares of the Company. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment The extended convertible note had a total carrying value of $163,341. As the common shares were issued as consideration for extending the convertible note, the fair value of the common shares of $8,268 was expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $8,268. ii. Second Modification: On June 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before November 30, 2021 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. iii. Third Modification: On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. iv. Fourth Modification: On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. As at February 29, 2024, the Company has recorded accrued interest of $36,681 (August 31, 2023 - $33,540), which is included in accounts payable and accrued liabilities on the consolidated balance sheets. As of February 29, 2024, the outstanding principal owing is $63,341 (August 31, 2023 - $63,341). On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and conversion price. c) On October 26, 2020, the Company issued a convertible note with a face value of $37,613 (the “Note”) and warrants to purchase 30,090 shares of the Company’s common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after April 23, 2021. The Note was convertible into shares of the Company’s common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, Derivatives and Hedging The relative fair values of the convertible note and the warrants were $20,176 and $17,437 respectively. The effective conversion price was then determined to be $0.65. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $20,176 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $17,437 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. i. First Modification: On June 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before November 30, 2021 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. ii. Second Modification: On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. iii. Third Modification: On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. As at February 29, 2024, the Company has recorded accrued interest of $12,572 (August 31, 2023 - $10,706), which is included in accounts payable and accrued liabilities on the consolidated balance sheets. As of February 29, 2024, the outstanding principal owing is $37,613 (August 31, 2023 - $37,613). On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and conversion price. d) On November 11, 2020, the Company issued a convertible note with a face value of $85,937 (the “Note”) and warrants to purchase 68,750 shares of the Company’s common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after May 9, 2021. The Note was convertible into shares of the Company’s common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, Derivatives and Hedging The relative fair values of the convertible note and the warrants were $48,258 and $37,679 respectively. The effective conversion price was then determined to be $0.70. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $48,258 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $37,679 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. i. First Modification: On June 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before November 30, 2021 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. ii. Second Modification: On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. iii. Third Modification: On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. As at February 29, 2024, the Company has recorded accrued interest of $28,348 (August 31, 2023 - $24,087), which is included in accounts payable and accrued liabilities on the consolidated balance sheets. As of February 29, 2024, the outstanding principal owing is $85,937 (August 31, 2023 - $85,937). On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and conversion price. e) On December 2, 2020, the Company issued a convertible note with a face value of $600,000 (the “Note”) and warrants to purchase 240,000 shares of the Company’s common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after November 27, 2021. The Note was convertible into shares of the Company’s common stock at any time prior to November 27, 2021 at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, Derivatives and Hedging The relative fair values of the convertible note and the warrants were $457,436 and $142,564 respectively. The effective conversion price was then determined to be $0.95. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $457,436 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $22,564 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. i. First Modification: On October 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied. As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. ii. Second Modification: On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. As at February 29, 2024, the Company has recorded accrued interest of $194,465 (August 31, 2023 - $164,712), which is included in accounts payable and accrued liabilities on the consolidated balance sheets. As of February 29, 2024, the outstanding principal owing is $600,000 (August 31, 2023 - $600,000). On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and conversion price. f) On January 7, 2021, the Company issued a convertible note with a face value of $300,000 (the “Note). The Note bears interest at 10% per annum and is due on demand after November 27, 2021. The Note was convertible into shares of the Company’s common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Note under ASC 815-15, Derivatives and Hedging i. First Modification: On October 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied. As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. ii. Second Modification: On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration. The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method. As at February 29, 2024, the Company has recorded accrued interest of $67,397 (August 31, 2023 - $52,521), which is included in accounts payable and accrued liabilities on the consolidated balance sheets. As of February 29, 2024, the outstanding principal owing is $300,000 (August 31, 2023 - $300,000). On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and conversion price. g) On March 26, 2021, the Company issued a convertible note with a face value of $18,000 (the “Note”) and warrants to purchase 18,000 shares of the Company’s common stock at $0.50 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after September 26, 2021. The Note was convertible into shares of the Company’s common stock at any time prior to September 26, 2021 at a conversion price of $1.25 per share. The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, Derivatives and Hedging The relative fair values of the convertible note and the warrants were $10,096 and $7,904 respectively. The effective conversion price was then determined to be $0.70. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature (“BCF”). The Company recognized the relative fair value of the BCF of $4,016 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $7,904 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $6,080. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. i. First Modification: On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The

Equity

Equity	6 Months Ended
Equity	Feb. 29, 2024
Equity
Equity	10. Equity During the six months ended February 28, 2023: On September 21, 2022, the Company issued 1,350,000 shares of common stock at $0.40 per share for $540,000 subscriptions received during the year ended August 31, 2022. On October 7, 2022, the Company issued 1,575,000 shares of common stock at $0.40 per share for proceeds of $630,000. In connection with the financing, the Company incurred finder’s fee of $10,000 and share issuance costs of $2,792. On October 7, 2022, the Company issued 75,000 shares of common stock with a fair value of $44,606 to settle related party accounts payable of $30,000, resulting in a loss on settlement of $14,606. On October 7, 2022, the Company issued 70,560 shares of common stock with a fair value of $41,966 to settle $29,529 in debt, resulting in a loss on settlement of $12,437. During the six months ended February 28, 2024: On September 5, 2023, the Company issued 150,000 shares of common stock at $0.20 per share for $30,000 subscriptions received during the year ended August 31, 2023. On October 20, 2023, the Company issued 100,000 shares of common stock at $0.20 per share for $20,000 subscriptions received during the year ended August 31, 2023. On December 1, 2023, the Company issued 1,730,000 shares of common stock at $0.20 per share for $346,000 subscriptions received during the year ended August 31, 2023. On December 1, 2023, the Company issued 2,201,990 shares of common stock at $0.20 per share for proceeds of $440,398. In connection with the financing, the Company issued 42,000 shares with a fair value of $3,024 as a finder’s fee. At February 29, 2024, the Company had received $30,000 in cash for shares subscriptions at $0.20 per share.

Related party transactions and

Related party transactions and balances	6 Months Ended
Related party transactions and balances	Feb. 29, 2024
Related party transactions and balances
Related party transactions and balances	11. Related party transactions and balances All transactions with related parties have occurred in the normal course of operations and are recorded at the exchange amount which is the amount agreed to by the Company and the related party. a) Key management compensation and related party transactions The Company has identified its directors and certain senior officers as its key management personnel. The compensation costs for key management personnel were as follows: Six Months Ended February 29, 2024 Six Months Ended February 28, 2023 Consulting fees and benefits $ 245,597 $ 195,231 Signing bonus 44,214 - $ 289,811 $ 195,231 b) Amounts due to related parties In the normal course of operations, the company shares certain administrative resources with companies related by common management and directors. The administrative resources and services, which were provided in the normal course of operations, were measured at the exchange. All amounts payable and receivable are non-interest bearing, unsecured and due on demand. The following table summarizes the amounts due to related parties: February 29, 2024 August 31, 2023 Chief Executive Officer and Director $ 186,279 $ 156,028 Chief Operating Officer and Director 224,403 201,612 An entity controlled by the Chief Financial Officer 109,919 84,962 Chief Business Development Officer 87,932 - An entity controlled by a Director 239,690 159,690 Director 94,669 91,000 $ 942,892 $ 693,292 As of February 29, 2024, the Company had $942,892 (August 31, 2023 - $693,292) payable to related parties. From this amount, $817,292 (August 31, 2023 - $623,292) was for expenses incurred or expensed paid on behalf of the Company by the parties and $125,600 (August 31, 2023 - $70,000) was for advances received from the parties.

Financial risk factors

Financial risk factors	6 Months Ended
Financial risk factors	Feb. 29, 2024
Financial risk factors
Financial risk factors	12. Financial risk factors The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows: a) Credit risk: Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company’s primary exposure to credit risk is on its cash account. Cash accounts are held with major banks in Canada. The Company has deposited its cash with a bank from which management believes the risk of loss is low. b) Liquidity risk: Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company’s approach to managing liquidity is to ensure that it will have sufficient liquidity to meet liabilities when due. Accounts payable are due within the current operating period. The Company has a working capital deficit and requires additional financing to meet its current obligations (see Note 1). c) Market risk: Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. The Company is not exposed to market risk. d) Interest rate risk: Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk, from time to time, on its cash balances. Surplus cash, if any, is placed on call with financial institutions and management actively negotiates favorable market related interest rates. e) Foreign exchange risk: Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar. The Company has not entered into any foreign currency contracts to mitigate risk, but manages the risk my minimizing the value of financial instruments denominated in foreign currency. The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Canadian dollars: February 29, 2024 February 28, 2023 Balance in Canadian dollars: Cash and cash equivalents $ - $ 26,547 Accounts receivable - 5,127 Accounts payable and accrued liabilities (1,205,467 ) (769,347 ) Net exposure (1,205,467 ) (737,673 ) Balance in US dollars: $ (888,333 ) $ (542,048 ) A 10% change in the US dollar to the Canadian dollar exchange rate would impact the Company’s net loss by approximately $88,833 for the six months ended February 29, 2024 (February 28, 2023 – $54,205). The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Colombian Pesos: February 29, 2024 February 28, 2023 Balance in Colombian Pesos dollars: Cash and cash equivalents $ 505,576 $ 684,128,157 Other receivables 660,410,427 139,323,503 Accounts payable (3,557,034,154 ) (4,158,486,022 ) Net exposure (2,896,118,151 ) (3,335,034,362 ) Balance in US dollars: $ (738,710 ) $ (686,690 ) A 10% change in the US dollar to the Colombian Peso exchange rate would impact the Company’s net loss by approximately $73,871 for the six months ended February 29, 2024 (February 28, 2023 - $68,669).

Capital management

Capital management	6 Months Ended
Capital management	Feb. 29, 2024
Capital management
Capital management	13. Capital management The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the business and continue as a going concern. The Company considers capital to be all accounts in equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company’s management to sustain future development of the business. The Company has a working capital deficit and requires additional capital to finance is future business plans. The Company is not subject to any externally imposed capital requirements.

Commitments

Commitments	6 Months Ended
Commitments	Feb. 29, 2024
Commitments
Commitments	14. Commitments a) As of February 29, 2024, the Company recorded a contingent liability of $547,190 (CAD$700,000) for expenses in connection with Allied Colombia acquisition, which is included in the balance of accounts payable and accrued liabilities on the consolidated balance sheet. b) The Company has entered into leases for farm land in Colombia. See Note 7 for details. c) In June 2019, the Company’s wholly owned subsidiary, AM Biosciences, signed a production and manufacturing contract to begin the manufacturing of the full building initially intended for the Canada extraction and production facility. The Company had determined to utilize these building assets in connection with potential United States operations in the State of Nevada upon on the occurrence or waiver of the changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States. In connection with that determination, on March 30, 2021, the Company’s wholly owned subsidiary, Allied US Products LLC, entered into a contingent asset purchase agreement (“Agreement”) to acquire two privileged licenses issued by the Nevada Department of Taxation purposed for the cultivation of cannabis (the “Licenses”). In consideration for the licenses, the Company agreed to pay $150,000, issue a $1,350,000 promissory note and assume certain liabilities. Concurrent with the execution of the Agreement, the Company’s wholly owned subsidiary, Tactical Relief LLC, agreed to enter into a 25-year land lease with the Fiore Subsidiary. As the Company made payments towards the purchase of the prefabricated buildings, various parts of the building were delivered to the property on the land lease. In December 2022, the Company was advised that the Fiore Subsidiary had become insolvent and that a trustee’s sale had been scheduled for the property which the Company had agreed to lease. In order to protect the Company’s interests, the Company filed a complaint in the Eighth Judicial District Court in Clark County, Nevada seeking injunctive relief to terminate the trustee’s sale or alternatively money damages. The Company filed a lis pendens against the property to reflect this complaint and to protect its interests in the building. However, the trustee’s sale went forward and the successful bidder claimed that the buildings were part of the real property and that it became the owner of the buildings. As a result, the Company filed suit, seeking a declaration of the Company’s ownership of the buildings as the buildings were personal property and not a part of the real property. A status conference was held for December 13, 2023 and during a further status conference on April 3, 2024 the court strongly suggested to proceed with the litigation. As a consequence, further discussions are ongoing..

Share purchase warrants

Share purchase warrants	6 Months Ended
Share purchase warrants	Feb. 29, 2024
Share purchase warrants
Share purchase warrants	15. Share purchase warrants The following table summarizes the continuity of share purchase warrants: Number of warrants Weighted average exercise price $ Balance, August 31, 2023 5,459,000 1.06 Expired (4,371,267 ) 1.25 Balance, February 29, 2024 1,087,733 0.28 As at February 29, 2024, the following share purchase warrants were outstanding: Number of warrants Exercise price $ Expiry date 20,000 1.25 March 7, 2024 67,733 1.25 May 27, 2024 1,000,000 0.20 July 30, 2025 1,087,733

Stock Options

Stock Options	6 Months Ended
Stock Options	Feb. 29, 2024
Stock Options
Stock Options	16. Stock options A summary of the Company’s stock option activity is as follows: Number of Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term Aggregate Intrinsic Value $ Balance, August 31, 2023 12,140,000 0.25 3.70 55,900 Granted 500,000 0.20 4.59 - Unearned performance-based options 300,000 0.20 4.59 - Outstanding, February 29, 2024 12,940,000 0.22 4.24 - Exercisable, February 29, 2024 11,606,667 0.22 4.25 - On December 20, 2024 the Company modified the exercise prices and maturity dates for previously granted and unexercised options as follows: Number of stock options Exercise price before modification Maturity date before modification Modified exercise price Modified maturity date 1,500,000 $0.25 February 1, 2026 $0.20 January 1, 2029 600,000 $0.22 February 1, 2026 $0.20 January 1, 2029 300,000 $0.25 May 1, 2027 $0.20 January 1, 2029 450,000 $0.22 May 1, 2027 $0.20 January 1, 2029 6,000,000 $0.24 March 8, 2028 $0.20 January 1, 2029 140,000 $0.20 June 3, 2028 $0.20 January 1, 2029 There was no other modification to the vesting schedule of the previously issued options. As a result, 8,990,000 unexercised options originally granted to purchase common stock at prices ranging from $0.20 to $0.25 per share were repriced. The repricing was treated as a modification of the original awards and the additional compensation costs for the difference between the fair value of the modified award and the fair value of the original award on the modification date was calculated. The repricing resulted in incremental stock-based compensation expense of $56,964, which was valued with the Black-Scholes option pricing model with the following weighted average assumptions: the risk-free rate of 4.17%; expected life of 2.73 years; volatility of 180%; forfeiture rate and dividend yield of nil; and the exercise price of $0.20. Expense related to vested shares was expensed on the repricing date and expense related to unvested shares will be amortized over the remaining vesting period. On January 1, 2024, the Company modified the exercise price and vesting terms for previously granted and unexercised options as follows: Number of stock options Exercise price before modification Vesting terms before modification Modified exercise price Modified vesting terms 300,000 $0.22 100,000 on October 1, 2024 100,000 on October 1, 2025 100,000 on October 1, 2026 $0.20 150,000 on January 1, 2024 150,000 on September 30, 2024 In addition, the Company granted additional 500,000 performance-based options with an exercise price of $0.20 which will vest 2 years from the achievement of specified performance conditions. As a result, 300,000 unexercised options originally granted to purchase common stock $0.22 per share were repriced along with the grant of 500,000 performance-based options. The repricing was treated as a modification of the original awards and the additional compensation costs for the difference between the fair value of the modified award and the fair value of the original award on the modification date was calculated. The repricing resulted in incremental stock-based compensation expense of $39,413, which was valued with the Black-Scholes option pricing model with the following weighted average assumptions: the risk-free rate of 3.93%; expected life of 4.75 years; volatility of 178%; forfeiture rate and dividend yield of nil; and the exercise price of $0.20. Expense related to vested shares was expensed on the repricing date and expense related to unvested shares will be amortized over the remaining vesting period. As at February 29, 2024, conditions for 200,000 performance-based options have been met with 100,000 options vesting on January 28, 2026 and 100,000 vesting on February 13, 2026. The Company estimates that all 500,000 performance-based options will vest and elected to account for forfeitures as they occur. During the six months ended February 29, 2024, the Company recorded stock-based compensation of $366,708 (2023 - $1,119,246) for options granted and vested during the period as consulting fees on the consolidated statement of operations. At February 29, 2024, there was $149,983 of unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Plan.

Non cash activities

Non cash activities	6 Months Ended
Non cash activities	Feb. 29, 2024
Non cash activities
Non-cash activities	17. Non-cash activities Six Months Ended February 29, 2024 Six Months Ended February 28, 2023 Non-cash activities: Shares issued to settle debt - 59,529 Shares issued as finder’s fee 3,024 -

Segment disclosure

Segment disclosure	6 Months Ended
Segment disclosure	Feb. 29, 2024
Segment disclosure
Segment disclosure	18. Segment disclosure The Company has two operating segments including: a) Allied Colombia, a Colombian based company through which the Company intends to commence commercial production in Colombia. (Allied Colombia) b) Allied Corp. which consists of the rest of the Company’s operations. (Allied) Factors used to identify the Company’s reportable segments include the organizational structure of the Company and the financial information available for evaluation by the chief operating decision-maker in making decisions about how to allocate resources and assess performance. The Company’s operating segments have been broken out based on similar economic and other qualitative criteria. The Company operates the Allied reporting segment in one geographical area (Canada), and the Allied Colombia reporting segment in one geographical area (Colombia). Financial statement information by operating segment for the six months ended February 29, 2024 is presented below: Allied $ Allied Colombia $ Total $ Gross margin - 17,036 17,036 Net loss (1,428,786 ) (273,713 ) (1,702,499 ) Depreciation and amortization 33,242 29,313 62,555 Total assets as of February 29, 2024 692,889 1,596,914 2,289,803 Geographic information for the six months ended and as at February 29, 2024 is presented below: Gross Margin $ Total Assets $ Canada - 692,889 Colombia 17,036 1,596,914 Total 17,036 2,289,803

Subsequent events

Subsequent events	6 Months Ended
Subsequent events	Feb. 29, 2024
Subsequent events
Subsequent events	19. Subsequent events a) On March 1, 2024, the Chief Executive Officer transferred his 2,500,000 shares back to treasury and forgave accrued consulting fees payable of $75,336. b) On March 20, 2024, the Vice President Corporate Development and Director resigned. c) On April 9, 2024, the Company entered into a securities purchase agreement and agreed to sell 2,500,000 shares of common stock at $0.20 per share for gross proceeds of $500,000. Pursuant to the agreement, the purchaser shall have the option to designate a member of the Board of Directors upon an additional investment of $750,000 over a period of twelve months. d) Subsequent to the period ended February 29, 2024, the Company amended the maturity dates of all convertible notes in default to December 31, 2024, and the conversion prices to the lesser of 80% of the twenty-day average closing price per share (but not less than $0.20 per share) or $0.50 per share.

Significant accounting polici_2

Significant accounting policies (Policies)	6 Months Ended
Significant accounting policies (Policies)	Feb. 29, 2024
Significant accounting policies
Principles of consolidation	These consolidated financial statements include accounts of Allied Corp. and its wholly-owned subsidiaries, including AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.
Cash and cash equivalents	Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. Cash equivalents are short-term, highly liquid investments with maturities within three months when acquired. The Company did not have any cash equivalents as of February 29, 2024 and August 31, 2023.
Property, plant and equipment	Property, plant and equipment are stated at cost. The Company depreciates the cost of property, plant and equipment over their estimated useful lives at the following annual rates and methods: Farm facility and equipment 1 - 10 years straight-line basis Office and computer equipment 5 - 10 years straight-line basis Land equipment 10 years straight-line basis
Inventory	Inventory is comprised of raw materials, supplies, vegetative and flowering plants, dried flower, diluted crude and CBD isolates available for sale, and purchased cannabis products. Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows.
Intangible assets	Intangible assets include licenses which are being amortized over their estimated useful lives of 10 years. The Company’s licenses are amortized over their economic or legal life on a straight-line basis, whichever is shorter. The licenses have been amortized from the date of acquisition. The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives. For long-lived assets, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.
Long-lived assets	In accordance with ASC 360, Property, Plant and Equipment
Foreign currency translation and functional currency conversion	Items included in these consolidated financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entities operate (the “functional currency”). Prior to September 10, 2019, the Company’s functional currency was the Canadian dollar. Translation gains and losses from the application of the U.S. dollar as the reporting currency during the period that the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss. The Company re-assessed its functional currency and determined as at September 10, 2019, its functional currency changed from the Canadian dollar to the U.S. dollar based on management’s analysis of changes in our organization. The change in functional currency was accounted for prospectively from September 10, 2019 and prior period financial statements were not restated for the change in functional currency. For periods commencing September 10, 2019, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after September 10, 2019 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transactions. Foreign exchange gains and losses are included in the statement of operations and comprehensive loss as foreign exchange gains. The Company assessed the functional currency for Allied Colombia to be the Colombian peso. The functional currency for all other subsidiaries is the U.S. dollar.
Share issuance costs	Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.
Research and development costs	Research and development costs are expensed as incurred. During the six months ended February 29, 2024, the Company incurred research and development costs of $nil (February 28, 2023 – $nil).
Advertising costs	Advertising costs are expensed as incurred. During the six months ended February 29, 2024, the Company incurred advertising costs of $631 (February 28, 2023 – $4,913).
Revenue Recognition	The Company’s revenue is comprised of sales of cannabis products. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Certain of the Company’s customer contracts may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.
Net income (loss) per common share	Net income (loss) per share is calculated in accordance with ASC 260, Earnings per Share Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.
Income taxes	The Company accounts for income taxes under ASC 740, Income Taxes
Related party transactions	Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.
Significant accounting estimates and judgments	The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern as described in Note 1.
Financial instruments	ASC 825, Financial Instruments Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The financial instruments consist principally of cash, due from related parties, accounts payable, note payable, and convertible notes payable. The fair value of cash when applicable is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all other financial instruments which are categorized as loans and receivables approximate their current fair values because of their nature and respective relatively short maturity dates or current market rates of interest for similar instruments. For certain of the Company’s financial instruments, including accounts payable, due from related parties, notes and loans payable, the carrying amounts approximate their fair values due to the short maturities. The Company does not have any assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet as of February 29, 2024 and August 31, 2023 other than cash. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions.
Leases	The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. The Company uses the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7 – Leases.
Recent accounting pronouncements	In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective September 1, 2022. The adoption of ASU 2020-06 did not have an impact on the Company’s financial statements. The Company does not expect that recent accounting pronouncements or changes in accounting pronouncements during the six months ended February 29, 2024, are of significance or potential significance to the Company.

Significant accounting polici_3

Significant accounting policies (Tables)	6 Months Ended
Significant accounting policies (Tables)	Feb. 29, 2024
Significant accounting policies
Schedule of property plant and equipment estimated useful lives	Farm facility and equipment 1 - 10 years straight-line basis Office and computer equipment 5 - 10 years straight-line basis Land equipment 10 years straight-line basis

Inventory (Tables)

Inventory (Tables)	6 Months Ended
Inventory (Tables)	Feb. 29, 2024
Inventory
Schedule of Inventory	February 29, 2024 August 31, 2023 Work in progress $ 47,163 $ 80,094 Finished goods 396,527 27,416 Total inventory $ 443,690 $ 107,510

Deposits and advances (Tables)

Deposits and advances (Tables)	6 Months Ended
Deposits and advances (Tables)	Feb. 29, 2024
Deposits and advances
Schedule of deposits and advances	February 29, 2024 August 31, 2023 Prepayments for construction facility in Colombia $ 19,083 $ 26,354 Total deposits and advances $ 19,083 $ 26,354

Property plant and equipment (T

Property plant and equipment (Tables)	6 Months Ended
Property plant and equipment (Tables)	Feb. 29, 2024
Property plant and equipment
Schedule of property plant and equipment	Construction in process Farm facility and equipment Office and computer equipment Land equipment Total Cost August 31, 2023 $ 429,749 $ 1,346,373 $ 29,952 $ 29,525 $ 1,835,599 Additions - 2,038 - - 2,038 Foreign exchange 18,310 29,083 1,276 1,258 49,927 February 29, 2024 $ 448,059 $ 1,377,494 $ 31,228 $ 30,783 $ 1,887,564 Accumulated depreciation August 31, 2023 $ - $ 404,559 $ 7,700 $ 6,148 $ 418,407 Additions - 100,686 1,614 1,492 103,792 Foreign exchange - 14,514 363 295 15,172 February 29, 2024 $ - $ 519,759 $ 9,677 $ 7,935 $ 537,371 Net book value August 31, 2023 $ 429,749 $ 941,814 $ 22,252 $ 23,377 $ 1,417,192 February 29, 2024 $ 448,059 $ 857,735 $ 21,551 $ 22,848 $ 1,350,193

Intangible assets (Tables)

Intangible assets (Tables)	6 Months Ended
Intangible assets (Tables)	Feb. 29, 2024
Intangible assets
Schedule of intangible assets	Cost $ Foreign exchange $ Accumulated amortization $ Accumulated impairment $ February 29, 2024 Net carrying value $ August 31, 2023 Net carrying value $ Cannabis licenses 5,457,911 (468,035 ) (1,143,335 ) (3,801,667 ) 44,874 40,301 5,457,911 (468,035 ) (1,143,335 ) (3,801,667 ) 44,874 40,301

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Feb. 29, 2024
Leases
Schedule of components of lease expenses	$ Operating lease cost: Amortization of right-of-use assets 8,201 Interest on lease liabilities 5,277 Total operating lease cost 13,478
Schedule of supplemental cash flow and other information related to leases	$ Lease payments 13,478
Schedule of supplemental balance sheet information related to leases	$ Cost 159,870 Accumulated amortization (30,077 ) Foreign exchange (21,227 ) Net carrying value at February 29, 2024 108,566
Schedule of future minimum lease payments	$ 2024 13,774 2025 27,547 2026 27,547 2027 27,547 2028 27,547 2029 27,547 2030 13,774 Total minimum lease payments 165,283 Less: amount of lease payments representing effects of discounting (56,717 ) Present value of future minimum lease payments 108,566 Less: current obligations under leases (12,070 ) Lease liabilities, net of current portion 96,496

Related party transactions an_2

Related party transactions and balances (Tables)	6 Months Ended
Related party transactions and balances (Tables)	Feb. 29, 2024
Related party transactions and balances
Schedule of related party compensation costs	Six Months Ended February 29, 2024 Six Months Ended February 28, 2023 Consulting fees and benefits $ 245,597 $ 195,231 Signing bonus 44,214 - $ 289,811 $ 195,231
Schedule of due from related party	February 29, 2024 August 31, 2023 Chief Executive Officer and Director $ 186,279 $ 156,028 Chief Operating Officer and Director 224,403 201,612 An entity controlled by the Chief Financial Officer 109,919 84,962 Chief Business Development Officer 87,932 - An entity controlled by a Director 239,690 159,690 Director 94,669 91,000 $ 942,892 $ 693,292

Financial risk factors (Tables)

Financial risk factors (Tables)	6 Months Ended
Financial risk factors (Tables)	Feb. 29, 2024
Financial risk factors
Schedule of foreign currency translation	February 29, 2024 February 28, 2023 Balance in Canadian dollars: Cash and cash equivalents $ - $ 26,547 Accounts receivable - 5,127 Accounts payable and accrued liabilities (1,205,467 ) (769,347 ) Net exposure (1,205,467 ) (737,673 ) Balance in US dollars: $ (888,333 ) $ (542,048 ) February 29, 2024 February 28, 2023 Balance in Colombian Pesos dollars: Cash and cash equivalents $ 505,576 $ 684,128,157 Other receivables 660,410,427 139,323,503 Accounts payable (3,557,034,154 ) (4,158,486,022 ) Net exposure (2,896,118,151 ) (3,335,034,362 ) Balance in US dollars: $ (738,710 ) $ (686,690 )

Share purchase warrants (Tables

Share purchase warrants (Tables)	6 Months Ended
Share purchase warrants (Tables)	Feb. 29, 2024
Share purchase warrants
Schedule of share purchase warrants	Number of warrants Weighted average exercise price $ Balance, August 31, 2023 5,459,000 1.06 Expired (4,371,267 ) 1.25 Balance, February 29, 2024 1,087,733 0.28 Number of warrants Exercise price $ Expiry date 20,000 1.25 March 7, 2024 67,733 1.25 May 27, 2024 1,000,000 0.20 July 30, 2025 1,087,733

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended
Stock Options (Tables)	Feb. 29, 2024
Stock Options
Schedule of Stock Options activity	Number of Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term Aggregate Intrinsic Value $ Balance, August 31, 2023 12,140,000 0.25 3.70 55,900 Granted 500,000 0.20 4.59 - Unearned performance-based options 300,000 0.20 4.59 - Outstanding, February 29, 2024 12,940,000 0.22 4.24 - Exercisable, February 29, 2024 11,606,667 0.22 4.25 -
Schedule of modification of exericse prices and maturity dates	Number of stock options Exercise price before modification Maturity date before modification Modified exercise price Modified maturity date 1,500,000 $0.25 February 1, 2026 $0.20 January 1, 2029 600,000 $0.22 February 1, 2026 $0.20 January 1, 2029 300,000 $0.25 May 1, 2027 $0.20 January 1, 2029 450,000 $0.22 May 1, 2027 $0.20 January 1, 2029 6,000,000 $0.24 March 8, 2028 $0.20 January 1, 2029 140,000 $0.20 June 3, 2028 $0.20 January 1, 2029
Schedule of modification of exercise price and vesting terms	Number of stock options Exercise price before modification Vesting terms before modification Modified exercise price Modified vesting terms 300,000 $0.22 100,000 on October 1, 2024 100,000 on October 1, 2025 100,000 on October 1, 2026 $0.20 150,000 on January 1, 2024 150,000 on September 30, 2024

Non cash activities (Tables)

Non cash activities (Tables)	6 Months Ended
Non cash activities (Tables)	Feb. 29, 2024
Non cash activities
Schedule of Non-cash activities	Six Months Ended February 29, 2024 Six Months Ended February 28, 2023 Non-cash activities: Shares issued to settle debt - 59,529 Shares issued as finder’s fee 3,024 -

Segment disclosure (Tables)

Segment disclosure (Tables)	6 Months Ended
Segment disclosure (Tables)	Feb. 29, 2024
Segment disclosure
Schedule of operating segment	Allied $ Allied Colombia $ Total $ Gross margin - 17,036 17,036 Net loss (1,428,786 ) (273,713 ) (1,702,499 ) Depreciation and amortization 33,242 29,313 62,555 Total assets as of February 29, 2024 692,889 1,596,914 2,289,803
Schedule of geographical information	Gross Margin $ Total Assets $ Canada - 692,889 Colombia 17,036 1,596,914 Total 17,036 2,289,803

Nature of operations reverse _2

Nature of operations reverse takeover transaction and going concern (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Nature of operations reverse takeover transaction and going concern
Net losses	$ (865,826)	$ (2,064,237)	$ (1,702,499)	$ (3,373,778)
Working capital deficit			$ (8,953,089)

Significant accounting polici_4

Significant accounting policies (Details)	6 Months Ended
Significant accounting policies (Details)	Feb. 29, 2024
Land Equipment [Member]
Estimated useful lives	10 years
Minimum [Member] \| Farm facility and equipment [Member]
Estimated useful lives	1 year
Minimum [Member] \| Office and Computer Equipment [Member]
Estimated useful lives	5 years
Maximum [Member] \| Farm facility and equipment [Member]
Estimated useful lives	10 years
Maximum [Member] \| Office and Computer Equipment [Member]
Estimated useful lives	10 years

Significant accounting polici_5

Significant accounting policies (Details Narrative) - USD ($)	6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023
Significant accounting policies
Intangible asset estimated useful life	10 years
Research and development costs	$ 0	$ 0
Advertising costs	$ 631	$ 4,913

Inventory (Details)

Inventory (Details) - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Inventory
Work-in-progress	$ 47,163	$ 80,094
Finished goods	396,527	27,416
Total inventory	$ 443,690	$ 107,510

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
Inventory (Details Narrative) - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Inventory
Write-off of inventory	$ 0	$ 43,861
Write-off of inventory additional		1,463,157
Net realizable value		0
Net realizable value additional	$ 443,690	$ 107,510

Deposits and advances (Details)

Deposits and advances (Details) - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Total deposits and advances	$ 19,083	$ 26,354
Prepayments for construction facility in Colombia [Member]
Total deposits and advances	$ 19,083	$ 26,354

Deposits and advances (Details

Deposits and advances (Details Narrative) - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Total deposits and advances	$ 19,083	$ 26,354
Prepayments for construction facility in Colombia [Member]
Total deposits and advances	$ 19,083	$ 26,354

Property plant and equipment (D

Property plant and equipment (Details)	6 Months Ended
Property plant and equipment (Details)	Feb. 29, 2024 USD ($)
Cost of asset, Beginning balance	$ 1,835,599
Cost of asset, Additions	2,038
Cost of asset, Foreign exchange	49,927
Cost of assets, Ending balance	1,887,564
Accumulated depreciation, Beginning balances	418,407
Accumulated depreciation, Additions	103,792
Accumulated depreciation, Foreign exchange	15,172
Accumulated depreciation, ending balance	537,371
Net book value, Beginning balance	1,417,192
Net book value , ending balance	1,350,193
Land Equipment [Member]
Cost of asset, Beginning balance	29,525
Cost of asset, Additions	0
Cost of asset, Foreign exchange	1,258
Cost of assets, Ending balance	30,783
Accumulated depreciation, Beginning balances	6,148
Accumulated depreciation, Additions	1,492
Accumulated depreciation, Foreign exchange	295
Accumulated depreciation, ending balance	7,935
Net book value, Beginning balance	23,377
Net book value , ending balance	22,848
Construction in progress [Member]
Cost of asset, Beginning balance	429,749
Cost of asset, Additions	0
Cost of asset, Foreign exchange	18,310
Cost of assets, Ending balance	448,059
Accumulated depreciation, Beginning balances	0
Accumulated depreciation, Additions	0
Accumulated depreciation, Foreign exchange	0
Accumulated depreciation, ending balance	0
Net book value, Beginning balance	429,749
Net book value , ending balance	448,059
Farm facility and equipment [Member]
Cost of asset, Beginning balance	1,346,373
Cost of asset, Additions	2,038
Cost of asset, Foreign exchange	29,083
Cost of assets, Ending balance	1,377,494
Accumulated depreciation, Beginning balances	404,559
Accumulated depreciation, Additions	100,686
Accumulated depreciation, Foreign exchange	14,514
Accumulated depreciation, ending balance	519,759
Net book value, Beginning balance	941,814
Net book value , ending balance	857,735
Office and Computer Equipment [Member]
Cost of asset, Beginning balance	29,952
Cost of asset, Additions	0
Cost of asset, Foreign exchange	1,276
Cost of assets, Ending balance	31,228
Accumulated depreciation, Beginning balances	7,700
Accumulated depreciation, Additions	1,614
Accumulated depreciation, Foreign exchange	363
Accumulated depreciation, ending balance	9,677
Net book value, Beginning balance	22,252
Net book value , ending balance	$ 21,551

Intangible assets (Details)

Intangible assets (Details) - USD ($)	6 Months Ended
Intangible assets (Details) - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Cost	$ 5,457,911
Foreign Exchange	(468,035)
Accumulated amortization	(1,143,335)
Accumulated impairment	(3,801,667)
Net carrying value	44,874	$ 40,301
Cannabis Licenses [Member]
Cost	5,457,911
Foreign Exchange	(468,035)
Accumulated amortization	(1,143,335)
Accumulated impairment	(3,801,667)
Net carrying value	$ 44,874	$ 40,301

Intangible assets (Details Narr

Intangible assets (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
Intangible assets (Details Narrative) - USD ($)	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2021	Feb. 17, 2020
Amortization of licenses	$ (1,143,335)
Other Intangible Assets [Licenses]
Impairment of intangible assets			$ 2,687,695
Amortization of licenses	$ 2,804	$ 5,683
Intangible Assets [Member] \| Allied Colombia [Member]
Amortization of licenses			658,836
Acquisition of licenses				$ 5,435,334
Amortization included in inventory			$ 158,121

Leases (Details)

Leases (Details)	6 Months Ended
Leases (Details)	Feb. 29, 2024 USD ($)
Operating lease cost:
Amortization of right-of-use assets	$ 8,201
Interest on lease liabilities	5,277
Total operating lease cost	$ 13,478

Leases (Details 1)

Leases (Details 1)	6 Months Ended
Leases (Details 1)	Feb. 29, 2024 USD ($)
Leases
Lease payments	$ 13,478

Leases (Details 2)

Leases (Details 2)	Feb. 29, 2024 USD ($)
Leases
Cost	$ 159,870
Accumulated amortization	(30,077)
Foreign exchange	(21,227)
Net carrying value	$ 108,566

Leases (Details 3)

Leases (Details 3)	Feb. 29, 2024 USD ($)
Leases
2024	$ 13,774
2025	27,547
2026	27,547
2027	27,547
2028	27,547
2029	27,547
2030	13,774
Total minimum lease payments	165,283
Less: amount of lease payments representing effects of discounting	(56,717)
Present value of future minimum lease payments	108,566
Less current obligations under leases	(12,070)
Lease liabilities, net of current portion	$ 96,496

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)		6 Months Ended
Leases (Details Narrative) - USD ($)	Aug. 10, 2021	Feb. 29, 2024	Aug. 31, 2021
Leases
Operating lease assets and liabilities		$ 82,398
Monthly payments	$ 2,647
Lease liabilities	$ 104,902		$ 70,705
Lease term	5 years
Weighted average remaining operating lease term		6 years

Loans payable (Details Narrativ

Loans payable (Details Narrative) - USD ($)		1 Months Ended			6 Months Ended		12 Months Ended
Loans payable (Details Narrative) - USD ($)	Jan. 03, 2024	Dec. 27, 2021	Nov. 20, 2020	Jun. 20, 2020	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2023	May 29, 2020
Proceed from short term loan	$ 100,000						$ 0
Initialy payment for building								$ 71,023
Monthly interest payments				$ 37,613
Repayment of Principal Amount			$ 1,253,772
Debt repayment description		the Company will make 27 monthly payments starting on January 20, 2022. For the first 3 months, the Company will make monthly payments of $37,613. For the remaining 24 months, the Company will make monthly payments of $66,288. If the first 6 monthly payments are made on time, the Company may prepay the unamortized loan balance with a 2% penalty of the remaining balance
Compensation cost fair value					$ 633
June 2020 [Member]
Purchase price of Building					1,253,772
Balance owing amount					1,968,327		$ 1,742,648
Interest paid on loans for purchase of buildings					0	$ 0
December 17, 2021 [Member]
Final payment on promissory notes					$ 295,543
Interest rate					8%
Interest payment					$ 15,000
Balance owing					294,867	284,700
Interest paid					$ 0	$ 0

Secured convertible notes pay_2

Secured convertible notes payable (Details Narrative) - USD ($)										1 Months Ended																	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 04, 2023	Dec. 07, 2022	Dec. 02, 2022	Jan. 11, 2022	Nov. 02, 2021	Oct. 02, 2021	Jan. 07, 2021	Dec. 02, 2020	Nov. 11, 2020	May 17, 2023	Feb. 28, 2023	Nov. 28, 2022	Jun. 16, 2022	Mar. 31, 2022	Mar. 29, 2022	Jan. 31, 2022	Dec. 23, 2021	Oct. 25, 2021	Jul. 25, 2021	Apr. 30, 2021	Apr. 29, 2021	Mar. 26, 2021	Oct. 26, 2020	Sep. 29, 2020	Jun. 30, 2020	Jan. 23, 2020	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2023	Dec. 01, 2022	Nov. 01, 2021	Oct. 01, 2021	Sep. 26, 2021
Relative fair value of convertible notes									$ 48,258														$ 20,176	$ 85,330					$ 0
Convertible notes payable	$ 50,000	$ 60,000		$ 150,000						$ 10,000	$ 150,000	$ 100,000	$ 250,000		$ 500,000	$ 100,000	$ 100,000	$ 100,000							$ 600,000			$ 150,000		$ 150,000		$ 70,000		$ 100,000
Simple interest rate	10%	10%	10%	10%	10%	10%				10%	10%	10%	10%		10%	10%	10%	10%
Beneficial conversion feature									48,258														20,176	85,330					$ 115,383
Conversion price	$ 0.20	$ 0.50		$ 1.25						$ 0.50	$ 0.50	$ 0.50	$ 1.25		$ 1.25	$ 1.25	$ 1.25	$ 1.25									$ 0.98	$ 0.50	$ 0.98	$ 0.50		$ 0.50		$ 1.25
Accrued interest included in accounts payable and accrued liabilities																											$ 36,681		$ 36,681		$ 33,540
Principal owing																											100,000		100,000		100,000
Warrants to purchase																		100,000																100,000
Convertible notes, Fair value																		$ 39,573																$ 40,117
Warrants, Fair value																																		$ 59,883
Relative fair value of warrants						$ 59,883			37,679									60,427					17,437	78,011					117,533
Relative fair value				$ 75,600		$ 40,117										$ 75,600	$ 40,800	$ 39,573
Warrant exercise price																		$ 1.25																$ 1.25
Additional paid in capital, fair value of warrants									$ 37,679							75,600		$ 60,427					$ 17,437	$ 78,011			108,100		108,100
Stock price																		$ 0.40																$ 0.40
Convertible debt				$ 74,400												$ 74,400	$ 59,200										364,517		364,517					$ 1,546
Original issue discount on beneficial conversion feature																											12,000		12,000
Convertible debt discounted																											108,100		108,100
Repayment Convertible notes payable																									200,000
Outstanding note payable																									200,000
Maturity date				Jul. 10, 2022		Mar. 31, 2022						Jun. 30, 2023	Dec. 16, 2022		Sep. 30, 2022	Jul. 10, 2022	Jun. 23, 2022	Mar. 31, 2022
Convertible notes payable																											3,774,891		3,774,891		3,724,891
Gain/Loss on extinguishment																											0	$ 0	0	$ (27,043)
Debt instrument, maturity term						1 year												1 year				1 year
January 11 2022 [Member]
Accrued interest																													31,973		24,534
Outstanding principal owing																											150,000		150,000		150,000
January 31 2022 [Member]
Accrued interest																													20,767		15,808
Outstanding principal owing																											100,000		100,000		100,000
March 29 2022 [Member]
Accrued interest																													96,028		71,233
Outstanding principal owing																											500,000		500,000		500,000
Two Convertible Notes [Member]
Convertible notes payable																										$ 200,000
Simple interest rate																										10%
Accrued interest																													28,329		23,370
Conversion price																										$ 1.25
Principal owing																											100,000		100,000		100,000
Accrued interests																											117,041		117,041		97,205
Warrant exercise price																										$ 1.25
Repayment Convertible notes payable																									$ 600,000	$ 600,000
Debt instrument, maturity term																										1 year
Warrants issued to purchase common shares																										240,000
Outstanding principal owing																											$ 400,000		$ 400,000		400,000
Debt discount																										$ 12,000
Eleven Convertible Notes Member
Convertible notes payable																				$ 180,000
Simple interest rate						10%															10%
Beneficial conversion feature																					$ 65,344
Conversion price																				$ 0.62							$ 1		$ 1
Relative fair value of warrants																					68,578
Warrant exercise price																				$ 1
Additional paid in capital, fair value of warrants								$ 22,564												$ 68,578
Original issue discount on beneficial conversion feature																				$ 46,078
Repayment Convertible notes payable																					$ 111,422
Debt instrument, maturity term																					1 year
Outstanding principal owing																											$ 180,000		$ 180,000		180,000
Accounts payable and accrued liabilities																											50,942		50,942		42,016
Warrants to purchase																					$ 180,000
Three Convertible Notes [Member]
Conversion price																								$ 1.25
Warrant exercise price																								$ 1.25
Repayment Convertible notes payable																								$ 163,341
Debt instrument, maturity term																								2 years
Warrants issued to purchase common shares																								130,673
Outstanding principal owing																											$ 63,341		63,341		63,341
Interest rate																								10%
Eaight Convertible Notes [Member]
Simple interest rate																						10%
Beneficial conversion feature																						$ 6,080
Accrued interest																													$ 67,397		52,521
Conversion price									$ 0.70													$ 1.25					$ 0.70		$ 0.70
Relative fair value of warrants																						$ 7,904
Relative fair value of convertible note																						$ 10,096
Warrant exercise price																						$ 0.50
Additional paid in capital, fair value of warrants																						$ 7,904
Repayment Convertible notes payable																						$ 18,000
Debt instrument, maturity term																						1 year
Outstanding principal owing																											$ 300,000		$ 300,000		300,000
Accounts payable and accrued liabilities																											5,272		5,272		4,379
Outstanding principal owing 1																											18,000		18,000		18,000
Warrants to purchase																						$ 18,000
Four Convertible Notes [Member]
Accrued interest																											12,572		12,572		10,706
Conversion price																							$ 1.25
Warrant exercise price																							$ 1.25
Repayment Convertible notes payable																							$ 37,613
Debt instrument, maturity term																							2 years
Warrants issued to purchase common shares																							30,090
Outstanding principal owing																											37,613		37,613		37,613
Interest rate																							10%
Five Convertible Notes [Member]
Accrued interest																											28,348		28,348		24,087
Conversion price									1.25
Warrant exercise price									$ 1.25
Repayment Convertible notes payable									$ 85,937
Debt instrument, maturity term									2 years
Warrants issued to purchase common shares									68,750
Outstanding principal owing																											85,937		85,937		85,937
Interest rate									10%					10%
One Convertible Notes [Member]
Convertible notes payable																										$ 400,000
Nine Convertible Notes [Member]
Convertible notes payable																											$ 35,000		$ 35,000
Simple interest rate																						10%
Beneficial conversion feature																						$ 33,772
Conversion price																						$ 1.25					$ 0.50		$ 0.50						$ 1.25
Relative fair value of warrants																						$ 43,914
Relative fair value of convertible note																						$ 56,086
Warrant exercise price																						$ 0.50
Additional paid in capital, fair value of warrants																						$ 43,914
Original issue discount on beneficial conversion feature																						22,314
Repayment Convertible notes payable																						$ 100,000
Debt instrument, maturity term																						1 year
Outstanding principal owing																											$ 35,000		$ 35,000
Warrants to purchase																						$ 100,000
Seven Convertible Notes [Member]
Simple interest rate							10%																						10%
Accrued interest																													$ 194,465		164,712
Conversion price							$ 1.25
Repayment Convertible notes payable							$ 300,000
Outstanding principal owing																											600,000		600,000		600,000
Ten Convertible Notes [Member]
Simple interest rate																				10%
Beneficial conversion feature																				$ 34,221
Conversion price																				$ 0.61
Relative fair value of warrants																				$ 38,507
Warrant exercise price																				$ 1
Additional paid in capital, fair value of warrants																				$ 38,507
Original issue discount on beneficial conversion feature																				27,272
Repayment Convertible notes payable																				61,493
Convertible notes payable																				$ 100,000
Debt instrument, maturity term																				1 year
Outstanding principal owing																											100,000		100,000		100,000
Accounts payable and accrued liabilities																											29,233		$ 29,233		24,274
Warrants to purchase																				$ 100,000
Six Convertible Notes [Member]
Simple interest rate								10%
Beneficial conversion feature								$ 457,436
Conversion price								$ 1.25
Relative fair value of warrants								$ 240,000
Warrant exercise price								$ 1.25
Repayment Convertible notes payable								$ 457,436
Convertible notes payable								$ 600,000
Debt instrument, maturity term								2 years
Relative fair values of convertible warrants								$ 142,564
On March 31, 2021 [Member] \| Two Convertible Notes [Member]
Simple interest rate																													10%
Outstanding note payable																													$ 400,000
Description of debt instrument																													As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument
Gain/Loss on extinguishment																													$ 20,000
Shares received by each noteholder																													10,000
Fair value of debt amount extingushed																													$ 20,000
Common shares issued upon debt conversion																													20,000
On March 31, 2021 [Member] \| Three Convertible Notes [Member]
Simple interest rate																													10%
Outstanding note payable																													$ 163,341
Description of debt instrument																													As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument
Gain/Loss on extinguishment																													$ 8,268
Shares received by each noteholder																													8,268
Fair value of debt amount extingushed																													$ 8,268
On March 31, 2022 [Member] \| Two Convertible Notes [Member]
Simple interest rate																													10%
On March 31, 2022 [Member] \| Eleven Convertible Notes Member
Simple interest rate																													10%
On March 31, 2022 [Member] \| Eight Convertible Notes [Member]
Simple interest rate																													10%
On March 31, 2022 [Member] \| Nine Convertible Notes [Member]
Simple interest rate																													10%
On March 31, 2022 [Member] \| Ten Convertible Notes [Member]
Simple interest rate																													10%
On October 1, 2021 [Member] \| Two Convertible Notes [Member]
Simple interest rate																													10%
On November 1, 2020 [Member] \| Two Convertible Notes [Member]
Outstanding note payable																													$ 400,000
Description of debt instrument																													As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument
Gain/Loss on extinguishment																													$ 110,000
Shares received by each noteholder																													50,000
Fair value of debt amount extingushed																													$ 110,000
Common shares issued upon debt conversion																													100,000
July 25 2021 [Member] \| Convertible Note [Member]
Simple interest rate																			10%
Beneficial conversion feature					$ 1,090
Conversion price																			$ 1.25
Convertible debt																																	$ 33,910
Maturity date																			Jan. 25, 2022
Convertible notes payable																			$ 35,000
Outstanding principal owing																											35,000		$ 35,000		35,000
Accounts payable and accrued liabilities																											9,071		9,071		7,336
July 25 2021 [Member] \| One Convertible Notes [Member]
Simple interest rate																			10%
Beneficial conversion feature					$ 467
Accrued interest																													3,888		3,144
Conversion price																			$ 1.25
Convertible debt																																	$ 14,533
Maturity date																			Jan. 25, 2022
Outstanding principal owing																											15,000		15,000		15,000
Convertible notes payable																			$ 15,000
December 23, 2021 [Member]
Convertible notes payable																	$ 100,000
Simple interest rate																	10%
Accrued interest																													21,836		16,877
Conversion price																	$ 1.25
Principal owing																											100,000		100,000		100,000
Relative fair value																	$ 40,800
Convertible debt																	$ 59,200
Maturity date																	Jun. 23, 2022
Outstanding principal owing																											$ 100,000		$ 100,000		100,000
On July 1, 2020 [Member] \| Two Convertible Notes [Member]
Simple interest rate																													5%
Conversion price																											$ 1.25		$ 1.25
Outstanding note payable																													$ 400,000
Description of debt instrument																													As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument
Gain/Loss on extinguishment																													$ 220,065
Shares received by each noteholder																													8,000
Fair value of debt amount extingushed																													$ 218,397
Common shares issued upon debt conversion																													16,000
Purchase additional common shares																													320,000
Warrants issued upon debt conversion																													160,000
On November 1, 2021 [Member] \| Eleven Convertible Notes Member
Simple interest rate					10%									10%															10%
On March 31, 2022 [Member] \| Three Convertible Notes [Member]
Simple interest rate																													10%
On June 1, 2021 [Member] \| Three Convertible Notes [Member]
Simple interest rate																													10%
December 23 2021 One [Member]
Accrued interest																													$ 24,082		19,123
Outstanding principal owing																											$ 100,000		100,000		100,000
October 25 2021 [Member]
Accrued interest																													23,425		18,466
Principal owing																											100,000		100,000		100,000
June 16 2022 [Member]
Accrued interest																													42,603		30,206
Outstanding principal owing																											250,000		250,000		250,000
November 28 2022 [Member]
Accrued interest																													12,575		7,616
Outstanding principal owing																											100,000		100,000		100,000
December 1 2022 [Member]
Accrued interest																													8,707		5,236
Principal owing																											70,000		70,000		70,000
December 7 2022 [Member]
Accrued interest																													7,364		4,389
Outstanding principal owing																											60,000		60,000		60,000
February 28 2023 [Member]
Accrued interest																													15,000		7,562
Outstanding principal owing																											150,000		150,000		150,000
May 17 2023 [Member]
Accrued interest																													786		50,000
Outstanding principal owing																											10,000		10,000		10,000
December 4 2023 [Member]
Accrued interest																													1,178		0
Outstanding principal owing																											$ 50,000		$ 50,000		$ 0

Equity (Detail Narrative)

Equity (Detail Narrative) - USD ($)	6 Months Ended
Equity (Detail Narrative) - USD ($)	Feb. 29, 2024	Feb. 28, 2023
Proceeds from issuanse of share	$ 786,398	$ 617,208
Price per share	$ 0.20
Cash received from share subscrptions	$ 30,000
Issue of common share [Member] \| September 21, 2022
Share issue price per share		$ 0.40
Common stock share issued		1,350,000
Subscription receive during period from issue of share		$ 540,000
Issue of common share [Member] \| October 7, 2022
Share issue price per share		$ 0.40
Common stock share issued		1,575,000
Subscription receive during period from issue of share		$ 630,000
Share issue cost		2,792
finder fee		$ 10,000
Issue of common share [Member] \| October 7, 2022 One
Common stock share issued		75,000
Fair value of issued of common stock		$ 44,606
Loss on settlement of related party account		14,606
Related party accounts payable		$ 30,000
Issue of common share [Member] \| October 7, 2022 Two
Common stock share issued		70,560
Fair value of issued of common stock		$ 41,966
Loss on settlement of related party account		12,437
Debt		$ 29,529
Issue of common share [Member] \| September 5, 2023
Share issue price per share	$ 0.20
Common stock share issued	150,000
Subscription receive during period from issue of share	$ 30,000
Issue of common share [Member] \| October 20, 2023
Share issue price per share	$ 0.20
Common stock share issued	100,000
Subscription receive during period from issue of share	$ 20,000
Issue of common share [Member] \| December 1, 2023 [Member]
Share issue price per share	$ 0.20
Common stock share issued	1,730,000
Subscription receive during period from issue of share	$ 346,000
Issue of common share [Member] \| December 1, 2023 One [Member]
Share issue price per share	$ 0.20
Common stock share issued	2,201,990
Common stock share issued for finder's fee, shares	42,000
Common stock share issued for finder's fee, value	$ 3,024
Proceeds from issuanse of share	$ 440,398

Related party transactions an_3

Related party transactions and balances (Details) - USD ($)	6 Months Ended
Related party transactions and balances (Details) - USD ($)	Feb. 29, 2024	Feb. 28, 2023
Related party transactions and balances
Consulting fees and benefits	$ 245,597	$ 195,231
Signing bonus	44,214	0
Total compensation costs	$ 289,811	$ 195,231

Related party transactions an_4

Related party transactions and balances (Details 1) - USD ($)	Feb. 29, 2024	Aug. 31, 2023
Amounts due from related party	$ 942,892	$ 693,292
Director [Member]
Amounts due from related party	94,669	91,000
CEO and Director [Member]
Amounts due from related party	186,279	156,028
COO and Director [Member]
Amounts due from related party	224,403	201,612
CFO [Member]
Amounts due from related party	109,919	84,962
An Entity Controlled By A Director [Member]
Amounts due from related party	239,690	159,690
Chief Business Development Officer [Member]
Amounts due from related party	$ 87,932	$ 0

Related party transactions an_5

Related party transactions and balances (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 29, 2024	Aug. 31, 2023
Related party transactions and balances
Due to related party	$ 942,892	$ 693,292
Advances received from related parties	125,600	70,000
Expensed paid to related parties	$ 817,292	$ 623,292

Financial risk factors (Details

Financial risk factors (Details) - USD ($)	Feb. 29, 2024	Aug. 31, 2023	Feb. 28, 2023
Accounts payable and accrued liabilities	$ 2,627,129	$ 2,393,359
Foreign Currency Exchange Member
Cash and cash equivalents	0		$ 26,547
Accounts receivable	0		5,127
Accounts payable and accrued liabilities	1,205,467		769,347
Net exposure	(1,205,467)		(737,673)
Balance in US dollars	$ (888,333)		$ (542,048)

Financial risk factors (Detai_2

Financial risk factors (Details 1) - Colombian Peso exchange rate [Member] - USD ($)	Feb. 29, 2024	Feb. 28, 2023
Cash and cash equivalents	$ 505,576	$ 684,128,157
Other receivables	660,410,427	139,323,503
Accounts payable	(3,557,034,154)	(4,158,486,022)
Net exposure	(2,896,118,151)	(3,335,034,362)
Balance in US dollars	$ (738,710)	$ (686,690)

Financial risk factors (Detai_3

Financial risk factors (Details Narrative) - USD ($)	6 Months Ended
Financial risk factors (Details Narrative) - USD ($)	Feb. 29, 2024	Feb. 28, 2023
Net losses	$ (1,702,499)	$ (3,373,778)
Foreign Currency Exchange Rate Member
Net losses	$ 88,833	$ 54,205
Exchange rate	10%	10%
Colombian Peso exchange rate [Member]
Net losses	$ 73,871	$ 68,669
Exchange rate	10%	10%

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	6 Months Ended
Commitments (Details Narrative) - USD ($)	Feb. 29, 2024	Feb. 28, 2023
Contingent liability	$ 547,190
Promissory note	100,000	$ 0
June 2019 [Member]
Company paid	150,000
Promissory note	$ 1,350,000

Share purchase warrants (Detail

Share purchase warrants (Details) - Warrants [Member]	6 Months Ended
Share purchase warrants (Details) - Warrants [Member]	Feb. 29, 2024 $ / shares shares
Number of warrants, Beginning balance \| shares	5,459,000
Number of warrants, expired \| shares	(4,371,267)
Ending balance \| shares	1,087,733
Weighted average exercise price, Beginning balance \| $ / shares	$ 1.06
Weighted average exercise price, expired \| $ / shares	1.25
Weighted average exercise price, Ending balance \| $ / shares	$ 0.28

Share purchase warrants (Deta_2

Share purchase warrants (Details 1) - $ / shares	Feb. 29, 2024	Oct. 25, 2021	Oct. 01, 2021
Number of warrant	1,087,733
Weighted average exercise price		$ 1.25	$ 1.25
Warrant 1 [Member]
Number of warrant	20,000
Weighted average exercise price	$ 1.25
Expiry date	Mar. 07, 2024
Warrant 2 [Member]
Number of warrant	67,733
Weighted average exercise price	$ 1.25
Expiry date	May 27, 2024
Warrant 3 [Member]
Number of warrant	1,000,000
Weighted average exercise price	$ 0.20
Expiry date	Jul. 30, 2025

Stock options (Details)

Stock options (Details)	6 Months Ended
Stock options (Details)	Feb. 29, 2024 USD ($) $ / shares shares
Stock Options
Number of warrants, Beginning balance \| shares	12,140,000
Number of options, granted \| shares	500,000
Number of options, unearned performance-based options \| shares	300,000
Ending balance \| shares	12,940,000
Number of options, Exercisable balance \| shares	11,606,667
Weighted Average exercise price, Beginnning balance \| $ / shares	$ 0.25
Weighted Average exercise price, granted \| $ / shares	0.20
Weighted Average exercise price, unearned performance-based options \| $ / shares	0.20
Weighted Average exercise price, exercisable balance \| $ / shares	0.22
Weighted average exercise price, Ending balance \| $ / shares	$ 0.22
Weighted average contractual term, beginning	3 years 8 months 12 days
Weighted average contractual term, granted	4 years 7 months 2 days
Weighted average contractual term, unearned performance-based options	4 years 7 months 2 days
Weighted average contractual term, outstanding	4 years 2 months 26 days
Weighted average contractual term, exercisable	4 years 3 months
Aggregate Intrinsic value, Beginning \| $	$ 55,900
Aggregate Intrinsic value, outstanding balance \| $	0
Aggregate Intrinsic value, Granted \| $	0
Aggregate Intrinsic value, unearned performance-based options \| $	0
Aggregate Intrinsic value, exercisable balance \| $	$ 0

Stock options (Details 1)

Stock options (Details 1)	1 Months Ended
Stock options (Details 1)	Dec. 20, 2024 $ / shares
Before Modification Stock Option 600,000 [Member]
Maturity date after modification	February 1, 2026
Exercise price before modification	$ 0.22
After Modification stock option 600,000 [Member]
Maturity date after modification	January 1, 2029
Exercise price before modification	$ 0.20
Before Modification Stock Option 300,000 [Member]
Maturity date after modification	May 1, 2027
Exercise price before modification	$ 0.25
After Modification stock option 300,000 [Member]
Maturity date after modification	January 1, 2029
Exercise price before modification	$ 0.20
Before Modification Stock Option 450,000 [Member]
Maturity date after modification	May 1, 2027
Exercise price before modification	$ 0.22
After Modification stock option 450,000 [Member]
Maturity date after modification	January 1, 2029
Exercise price before modification	$ 0.20
Before Modification Stock Option 6,000,000 [Member]
Maturity date after modification	March 8, 2028
Exercise price before modification	$ 0.24
After Modification stock option 6,000,000 [Member]
Maturity date after modification	January 1, 2029
Exercise price before modification	$ 0.20
Before Modification Stock Option 140,000 [Member]
Maturity date after modification	June 3, 2028
Exercise price before modification	$ 0.20
After Modification stock option 140,000 [Member]
Maturity date after modification	January 1, 2029
Exercise price before modification	$ 0.20
Before Modification Stock Option 1,500,000 [Member]
Maturity date after modification	February 1, 2026
Exercise price before modification	$ 0.25
After Modification stock option 1,500,000 [Member]
Maturity date after modification	January 1, 2029
Exercise price before modification	$ 0.20

Stock options (Details 2)

Stock options (Details 2) - $ / shares	Jan. 01, 2024	Oct. 25, 2021	Oct. 01, 2021
Number of stock options for modification of exercise price		$ 1.25	$ 1.25
Stock Option For Modification [Member]
Number of stock options for modification of exercise price and vesting term	300,000
Number of stock options for modification of exercise price	$ 0.22
Number of stock options for modified exercise price	$ 0.20
Stock Option For Modification [Member] \| October 1, 2024 [Member]
Number of stock options for modification of vesting terms before modification	100,000
Stock Option For Modification [Member] \| October 1, 2025 [Member]
Number of stock options for modification of vesting terms before modification	100,000
Stock Option For Modification [Member] \| October 1, 2026 [Member]
Number of stock options for modification of vesting terms before modification	100,000
Stock Option For Modification [Member] \| September 30, 2024 [Member]
Number of stock options for modified of vesting terms	150,000
Stock Option For Modification [Member] \| January 1, 2024 [Member]
Number of stock options for modified of vesting terms	150,000

Stock options (Details Narrativ

Stock options (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
Stock options (Details Narrative) - USD ($)	Feb. 29, 2024	Nov. 30, 2023	Feb. 28, 2023	Nov. 30, 2022	Feb. 29, 2024	Feb. 28, 2023	Oct. 25, 2021	Oct. 01, 2021
Stock-based compensation	$ 223,055	$ 143,653	$ 574,075	$ 545,171	$ 366,708	$ 1,119,246
Unrecognized compensation costs- related to non-vested stock-based compensation	$ 149,983				$ 149,983
Number of stock options for modification of exercise price							$ 1.25	$ 1.25
Additional Stock option [Member]
Number of stock options for modification of exercise price	$ 0.20				$ 0.20
Grant number of share					500,000
Vesting period					2 years
Granted Stock option [Member]
Stock-based compensation					$ 39,413
Expected dividend yield					0%
Expected volatility					178%
Expected life (in years)					4 years 9 months
Risk-free interest rate					3.93%
Number of stock options for modification of exercise price	0.22				$ 0.22
Grant number of share					300,000
Grant number of share performance-based options					500,000
Description related to performance-based options					As at February 29, 2024, conditions for 200,000 performance-based options have been met with 100,000 options vesting on January 28, 2026 and 100,000 vesting on February 13, 2026. The Company estimates that all 500,000 performance-based options will vest and elected to account for forfeitures as they occur
Stock Option One [Member]
Stock-based compensation					$ 56,964
Expected dividend yield					0%
Expected volatility					180%
Expected life (in years)					2 years 8 months 23 days
Risk-free interest rate					4.17%
Number of stock options for modification of exercise price	$ 0.20				$ 0.20
Unexercised options originally granted to purchase common stock					8,990,000
Exercise price of common stock					from $0.20 to $0.25

Noncash activities (Details)

Noncash activities (Details) - Non-Cash Activities [Member] - shares	6 Months Ended
	Feb. 29, 2024	Feb. 28, 2023
Shares issued to settle debt		59,529
Shares issued as finder's fee	3,024

Segment disclosure (Details)

Segment disclosure (Details) - USD ($)	3 Months Ended		6 Months Ended
Segment disclosure (Details) - USD ($)	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2023
Gross margin	$ 0	$ 0	$ 17,036	$ 43,667
Net losses	(865,826)	$ (2,064,237)	(1,702,499)	(3,373,778)
Depreciation and amortization			62,555	$ 57,429
Total assets	2,289,803		2,289,803		$ 2,063,728
Allied [Member]
Gross margin			0
Net losses			(1,428,786)
Depreciation and amortization			33,242
Total assets	692,889		692,889
Allied Colombia [Member]
Gross margin			17,036
Net losses			(273,713)
Depreciation and amortization			29,313
Total assets	$ 1,596,914		$ 1,596,914

Segment disclosure (Details 1)

Segment disclosure (Details 1) - USD ($)	3 Months Ended		6 Months Ended
Segment disclosure (Details 1) - USD ($)	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023	Aug. 31, 2023
Gross margin	$ 0	$ 0	$ 17,036	$ 43,667
Total assets	2,289,803		2,289,803		$ 2,063,728
Canada [Member]
Gross margin			0
Total assets	692,889		692,889
Colombia [Member]
Gross margin			17,036
Total assets	$ 1,596,914		$ 1,596,914

Subsequent events (Details Narr

Subsequent events (Details Narrative) - Subsequent Event [Member] - Chief Executive Officer [Member] - USD ($)		1 Months Ended
	Apr. 09, 2024	Mar. 31, 2024	Mar. 01, 2024
Number of shars transfer to treasury			2,500,000
Number of common stock sale	2,500,000
Accrued consulting fees payable			$ 75,336
Gross proceeds from sale of stock	$ 500,000
Description related to Board of Director	additional investment of $750,000 over a period of twelve months.
Description related to maturity date of convertible note		convertible notes in default to December 31, 2024, and the conversion prices to the lesser of 80% of the twenty-day average closing price per share (but not less than $0.20 per share) or $0.50 per share
Number of common stock sale price	$ 0.20